Nurix Therapeutics has launched the DAYBREAK-CLL-201 trial of bexobrutideg in relapsed or refractory chronic lymphocytic leukemia, advancing its CLL pipeline. T

Nurix Therapeutics has launched the DAYBREAK-CLL-201 trial of bexobrutideg in relapsed or refractory chronic lymphocytic leukemia, advancing its CLL pipeline. The oral BTK degrader is backed by a Roche partnership, underscoring the program’s strategic importance.